[Media Releases] Focusing on Antibody-Drug Conjugates… Aiming for KRW 5 bn revenue through out-licensing (Etoday, 12 Aug 2014)
Title: Focusing on Antibody-Drug Conjugates… Aiming for KRW 5 bn revenue through out-licensing Publication: Etoday / Eugene Kim Date: 12 Aug 2014 URL: link to website (contents in Korean)
· LegoChem, a biotech founded in 2006, discovers and develops antibiotics, anti-coagulants, and oncology drugs based on medicinal chemistry. Enlisted on KOSDAQ in May 2013. · Antibody-Drug Conjugates (ADCs) technology is LegoChem’s key growth driver and is a next-generation technology that has achieved site-specificity and stability which have been the major stakes of the first generation technologies. · ADC is a platform technology that can be out-licensed to pharmaceuticals to generate potential license fees and milestone payments per target; thus numerous number of licensing deals are available with this technology. · With is advanced technology, LegoChem has recently been selected as one of the “K-Brain Power” companies by the Ministry of Trade, Industry, and Energy in Korea. · The management of LegoChem has emphasized that the value of the company lies in the future when its pipeline ultimately translates into significant value.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |